HP and idiopathic pulmonary fibrosis: The ELISA assay, performed in a new cohort composed of 10 healthy samples and 14 IPF, before and after 1 year of treatment, confirmed the high abundance of haptoglobin in the serum of the patients after one year of treatment with nintedanib (healthy 1,3 × 106 ± 0,2 × 106; T0 3,6 × 106 ± 1,7 × 106; T1 4,2 × 106 ± 1,4 × 106 ng/ml).